Group 7 Copy 3 Created with Sketch.
News Issue Archive Device Guide Calendar Subscribe Advertising

MENU

Centers

Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous

News Current Issue Archive Device Guide Calendar Subscribe Advertising About Contact Privacy Submissions
Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous

Advertisement

Advertisement

Search Results

Show Filters

close Created with Sketch.

Refine by Content Type

close Created with Sketch.

Refine by Year

close Created with Sketch.

Advertisement

Sort By:

Relevance Date

Choose Sites to Search:

EVToday EVToday + CIToday

evt | Article | May 2019

Mentors and Protégés: Conversations on Career and Craft With Riad Salem, MD

Alexander Logsdon, DO, and Adam Sucher, DO, talk with Dr. Salem about balancing research and clinical responsibilities, his journey in establishing Y-90 as a standard of care, and his advice to aspiring clinical researchers, among other topics.

evt | Article | April 2012 Supplement

Tortuous Hepatic Artery Embolization Using the Fathom® Guidewire

By Riad Salem, MD, MBA, Northwestern Memorial Hospital

evt | Article | August 2017

Practical IR Approach to Early Stage Hepatocellular Carcinoma

Moderator: Robert J. Lewandowski, MD, FSIR
Panel: Daniel B. Brown, MD, FSIR; Riad Salem, MD, MBA, FSIR; and Fred T. Lee Jr, MD

Sponsored by Cook Medical

evt | Article | December 2021 Supplement

Embolization | Harnessing the Clinical and Economic Power of Pushable Coils

Moderator: Scott O. Trerotola, MD;
Panelists: Sarah White, MD; Daniel Brown, MD; Riad Salem, MD, MBA; and Alan H. Matsumoto, MD, FACR, FSIR, FAHA

Advertisement

Advertisement

evt | Article | June 2008

Yttrium-90 Radioembolization

Recent advances in hepatic embolotherapy.

By David M. Liu, MD, FRCP(C); David N. Cade, MD; Jesse Knight, MD; Rodney Raabe, MD; Stephen Kee, MD; Andrew Kennedy, MD, FACRO; and Riad Salem, MD, FSIR, MBA

Sponsored by Boston Scientific Corporation

evt | Article | April 2021

Making Critical Radioembolization Therapy Available for More Patients With Hepatocellular Carcinoma

TheraSphere™ Y-90 Glass Microspheres are the only radioembolization therapy FDA-approved for HCC.

By Riad Salem, MD, MBA

evt | Article | October 2018

Technical Dos and Don'ts of Radiation Segmentectomy and Same-Day Y-90 Treatment

Contemporary radioembolization techniques and the approaches to avoid.

By Ahmed Gabr, MD; Robert J. Lewandowski, MD, FSIR; Riad Salem, MD; and Ahsun Riaz, MD

evt | Article | October 2024

TARE in Advanced HCC: When Is It Optimal and Why?

International perspectives on when to utilize transarterial radioembolization to increase the likelihood of curative outcomes in patients with advanced-stage hepatocellular carcinoma.

With Jin Woo Choi, MD, PhD, and Riad Salem, MD, MBA

evt | News | August 30, 2016

Y-90 Radioembolization Compared With Chemoembolization for Hepatocellular Carcinoma

August 31, 2016—Online ahead of print in Gastroenterology, Riad Salem, MD, et al published findings from a randomized, phase 2 study comparing the effects of treating patients with hepatocellular carcinoma (HCC) with conventional transarterial chemoembolization (cTACE) versus a minimally invasive radioembolization procedure using implanted radioactive micron-sized particles loaded with yttrium-90 (Y-90) inside the blood vessels that supply a tumor.

evt | Article | October 2022

Roundtable Discussion: Has Interventional Oncology Established Itself as the Fourth Pillar of Oncology?

Top interventional oncology voices discuss the additional needs for the specialty, the most important developments to date, how interventional oncology interacts with interventional radiology and diagnostic radiology, and their hopes for interventional oncology in the future.

Moderator: Suvranu Ganguli, MD, FSIR;
Panelists: Karen Brown, MD, FSIR; Riad Salem, MD, MBA; and Michael C. Soulen, MD

evt | News | December 25, 2017

Northwestern 15-Year Experience Informs Institutional Decision to Adopt Y-90 TARE as Primary Treatment for HCC

December 26, 2017— Findings from a study of yttrium-90 (Y-90) transarterial radioembolization (TARE) were published by Riad Salem, MD, et al online ahead of print in Hepatology.

evt | News | December 21, 2017

Y-90 Radioembolization Studied for Locally Advanced HCC With Portal Vein Thrombosis

December 21, 2017—Online in Journal of Nuclear Medicine, Nadine Abouchaleh et al reported survival outcomes for advanced stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with yttrium-90 (Y-90) radioembolization.

evt | News | April 26, 2018

Radiation Segmentectomy Studied to Treat Liver Cancer

April 27, 2018—The Radiological Society of North America (RSNA) announced that findings from a study of radiation segmentectomy (RS) as a curative treatment option for patients with early stage hepatocellular carcinoma (HCC) were published online by Robert J. Lewandowski, MD, et al in RSNA's Radiology. The study's Senior Investigator is Riad Salem, MD, who is Chief of Vascular Interventional Radiology in the Department of Radiology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Sponsored by Cook Medical

evt | Article | December 2021 Supplement

Providing a Comprehensive Approach to Vascular Disease

By Mark Breedlove

evt | Article | November 2024

Mentors and Protégés: Conversations on Career and Craft With Dr. Robert J. Lewandowski, MD, FSIR (2024)

Shakthi Kumaran Ramasamy, MD, Co-Chair of the Research and Innovation Committee of the Society of Interventional Radiology Resident, Fellow, and Student section, talks with Dr. Lewandowski about his career trajectory, research endeavors, mentorship, and more.

evt | News | September 20, 2021

Boston Scientific’s TheraSphere Y-90 Glass Microspheres Evaluated in Phase 3 EPOCH Trial to Treat Metastatic Colorectal Cancer

September 20, 2021—Boston Scientific Corporation announced that the EPOCH clinical trial of the company’s TheraSphere yttrium-90 (Y-90) glass microspheres met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) of patients with metastatic colorectal cancer (mCRC) of the liver.

evt | News | November 18, 2013

Boston Scientific's Direxion Torqueable Microcatheter Receives FDA Clearance and CE Mark Approval

November 19, 2013—Boston Scientific Corporation (Natick, MA) announced that it has received US Food and Drug Administration clearance and European CE Mark approval for its Direxion torqueable microcatheter, part of its portfolio of peripheral embolization technologies used primarily by interventional radiologists to treat liver cancer, uterine fibroids, and other challenging conditions.  According to Boston Scientific, the Direxion device is designed to facilitate selective access and delivery of diagnostic, embolic, and therapeutic materials into the peripheral vasculature.

evt | Article | June 2008

Embolization Therapies

By Barry T. Katzen, MD, Chief Medical Editor

evt | Article | October 2024

Interventional Oncology: Exploring the Boundaries

By Edward Kim, MD, FSIR

evt | News | March 18, 2021

FDA Approves Boston Scientific’s TheraSphere Y-90 Glass Microsphere to Treat HCC

March 18, 2021—Boston Scientific Corporation announced it has received FDA approval of the TheraSphere Y-90 glass microspheres for the treatment of patients with hepatocellular carcinoma (HCC).


1
2
3

Advertisement

Advertisement

Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous
Centers

Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous

News• Current Issue• Archive• Device Guide• Advertising• About Calendar• Contact• Privacy• Submissions• Subscriptions


Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field.



magazine Created with Sketch.

Free Print Subscriptions

Fill 1 Created with Sketch.

Email Newsletter



twitter-icon LinkedIn Created with Sketch. instagram BlueSky-Circle
Cardiac Interventions Today
Group 7 Copy 3 Created with Sketch.
bmc-secondary-mark-color copy Created with Sketch.

© 2026 Bryn Mawr Communications II, LLC.  
All Rights Reserved   •   Privacy Policy

one-trust-button